The Effects of Losartan on Attention Control: An Eye-tracking Study
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 80
- 试验地点
- 1
- 主要终点
- Saccade/antisaccade latency difference between social and non-social stimuli after losartan administration
研究概览
简要总结
The main aim of the present study is to investigate the effects of orally administered Losartan on bottom-up and top-down attentional control to socio-emotional stimuli by combining a validated saccade/antisaccade eye-tracking paradigm with a randomized between-subject placebo-controlled pharmacological trial design.
详细描述
Animal models and initial findings in humans suggest that the angiotensin II antagonist Losartan may have neuroprotective effects and could potentially enhance cognitive functions, including valence-specific attention and regulatory control. Within this context the present study aims to examine whether angiotensin II blockade via Losartan modulates top-down and bottom-up attentional control towards socio-affective stimuli. To this end, healthy individuals will undergo a double-blind, between-subjects, placebo-controlled pharmaco-eye-tracking experiment and receive a single oral dose of Losartan (50 mg) or placebo before performing a saccade/anti-saccade task 90 minutes after administration. The task paradigm will encompass social (happy, angry, fearful, sad and neutral faces) and non-social (oval) stimuli to examine general as well as social and emotion-specific effects of oral losartan.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Basic Science
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 40 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Healthy subjects who volunteer to participate and are able to fully understand and agree with this study by written informed consent.
- •Normal or corrected-normal version
排除标准
- •History of neuropsychiatric diseases.
- •History of cardiac disease, including arrhythmias, aortic stenosis, or congestive heart failure; history of syncope or unexplained loss of consciousness.
- •History of hepatic diseases, including cholestasis, biliary obstructive disease, or severe liver dysfunction.
- •History of renal diseases, including renal stones or renal failure.
- •History of hyponatremia(Serum sodium <135mmol/L) or hyperkalemia (Serum potassium>5.5mmol/L); history of diabetes mellitus or diabetes insipidus
- •Known hypersensitivity or allergic reaction to any medication or hormone; strong allergic reaction to food.
- •Infections such as COVID-19 or influenza, or unexplained fever.
- •Subjects with hypertension (BP ≥130/80mmHg) or hypotension (BP ≤ 90/60mmHg).
- •History of alcohol or drug abuse; smoker (≥ 10 cigarettes or ≥ 3 cigars or ≥ 3 pipes/day); smoker using e-cigarettes.
- •Blood donation (≤ 1 month prior to administration).
- •Take oral contraceptives or receive hormonal medications in the three months prior to the experiment.
- •Pregnant or breastfeeding.
研究组 & 干预措施
Losartan group
Losartan tablet(50 mg)
干预措施: Losartan (Drug)
Placebo group
Placebo tablet
干预措施: Placebo (Drug)
结局指标
主要结局
Saccade/antisaccade latency difference between social and non-social stimuli after losartan administration
时间窗: 90 minutes - 120 minutes after treatment
Comparison between social-specific saccade/antisaccade latencies (in milliseconds) between the losartan and placebo treatment conditions.
Error rate of saccade/antisaccade for social versus non-social stimuli after losartan administration
时间窗: 90 minutes - 120minutes after treatment
Comparison between social-specific error rates of saccade/antisaccade between the losartan and placebo treatment conditions.
次要结局
- Saccade/antisaccade latency for different facial emotions after losartan administration(90 minutes - 120 minutes after treatment)
- Error rate of saccade/antisaccade for different facial emotions after losartan administration(90 minutes - 120 minutes after treatment)
研究者
Benjamin Becker
Professor
University of Electronic Science and Technology of China